Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q3 2025
Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.
Number of contributors: 6 (all of which have been updated or confirmed before the report)
| KPI (MSEK, unless otherwise specified) | Q3 2025E |
| Net sales | 185 |
| Organic growth in local currency (%) | -0.30 |
| Gross profit | 138 |
| EBITDA | 30.4 |
| EBIT | 12.6 |
| Net profit | 9.56 |
| Earnings per share (SEK) | 0.31 |
XVIVO Perfusion’s Q3 report will be released on Thursday 23 October at 07.30 CEST.